Are you using the commercially available Naveris assay for HPV+ OPX cancers in your practice?
Based on the JCO 2020 paper, how are you using this information?
I understand there is no data to change management and most of us will be hesitant to do so at this point. But can this help to change the frequency/modality of surveillance?
Community PollStarted
Are you using the commercially available Naveris (NavDx, Chera JCO 2020) assay for HPV+ OPX cancers in your practice?
96 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Radiation Oncology · Emory University
Answered on
Our practice at Emory is to get this at initial consult for all HPV+ oropharyngeal cancers so that we can establish if ctHPVDNA is positive (as it is not positive in all HPV+ cases).
Right now, I find it most useful at the three month scan in equivocal cases, a negative ctHPVDNA leads us more towar...
Join for free or sign in to see the full answer